123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jolanta M. Durski ◽  
Carrie B. Hruska ◽  
Trond V. Bogsrud ◽  
Mabel Ryder ◽  
Geoffrey B. Johnson
Keyword(s):  
Thyroid Cancer ◽  
Whole Body ◽  
131I Treatment ◽  
Body Retention ◽  
Metastatic Thyroid Cancer

scholarly journals Whole-Body Radioiodine Effective Half-Life in Patients with Differentiated Thyroid Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1740
Author(s):  
Michele Klain ◽  
Carmela Nappi ◽  
Marina De Risi ◽  
Leandra Piscopo ◽  
Fabio Volpe ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Half Life ◽  
Differentiated Thyroid Cancer ◽  
Multivariable Analysis ◽  
Whole Body ◽  
131I Therapy ◽  
Retention Data ◽  
Remnant Ablation ◽  
131I Treatment ◽  
Body Retention

Background: Radioactive 131I (RAI) therapy is used in patients with differentiated thyroid cancer (DTC) after total thyroidectomy for remnant ablation, adjuvant treatment or treatment of persistent disease. 131I retention data, which are used to indicate the time at which a 131I treated DTC patient can be released from the hospital, may bring some insights regarding clinical factors that prolong the length of hospitalization. The aim of this study was to investigate the 131I whole-body retention in DTC patients during 131I therapy. Methods: We monitored 166 DTC patients to follow the 131I whole-body retention during 131I therapy with a radioactivity detector fixed on the ceiling of each protected room. A linear regression fit permitted us to estimate the whole-body 131I effective half-life in each patient, and a relationship was sought between patients’ clinical characteristics and whole-body effective 131I half-life. Results: The effective 131I half-life ranged from 4.08 to 56.4 h. At multivariable analysis, longer effective 131I half-life was related to older age and extensive extra-thyroid disease. Conclusions: 131I effective half-life during 131I treatment in DTC patients is highly variable among patients and is significantly longer in older and in patients with RAI uptake in large thyroid remnants or in extrathyroidal disease that significantly prolongs the whole-body retention of 131I.

scholarly journals Comparison of whole body retention of I-131 in case humans thyroid cancer between model prediction and measurement

2017 ◽  
Vol 2 (1) ◽  
Author(s):  
Brudecki Kamil ◽  
Mroz Tomasz ◽  
Janowski Paweł ◽  
Lorenc-Brudecka Jadwiga
Keyword(s):  
Thyroid Cancer ◽  
Model Prediction ◽  
Whole Body ◽  
Body Retention

131I whole body retention (WBR), thyroid scan and/or thyroglobulin (Tg) in the assessment of thyroid cancer

1993 ◽  
Vol 14 (3) ◽  
pp. 235 ◽  
Author(s):  
M. J. O??Doherty ◽  
J. I. Gaunt ◽  
C. J. Page ◽  
T. O. Nunan ◽  
D. N. Croft
Keyword(s):  
Thyroid Cancer ◽  
Whole Body ◽  
Thyroid Scan ◽  
Body Retention

Hiatal Hernia on Whole-Body Radioiodine Survey Mimicking Metastatic Thyroid Cancer

1993 ◽  
Vol 18 (9) ◽  
pp. 751-753 ◽  
Author(s):  
J A SCHNEIDER ◽  
C R DIVGI ◽  
A M SCOTT ◽  
H A MACAPINLAC ◽  
M SONENBERG ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Hiatal Hernia ◽  
Whole Body ◽  
Metastatic Thyroid Cancer

Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer

1997 ◽  
pp. 254-261 ◽  
Author(s):  
J Pachucki ◽  
LA Burmeister
Keyword(s):  
Thyroid Cancer ◽  
High Rate ◽  
Whole Body ◽  
High Dose ◽  
Serum Thyroglobulin ◽  
131I Treatment ◽  
Measurable Serum ◽  
Well Differentiated ◽  
Therapeutic Doses ◽  
Post Therapy

Whereas in the past a negative diagnostic 131I whole body scan (WBS) was interpreted as the lack of significant residual or recurrent thyroid cancer, today the patient with negative WBS and measurable serum thyroglobulin (Tg) presents a diagnostic and therapeutic dilemma. Previous studies have shown a high rate of visualization of uptake and a decrease in Tg after one or more therapeutic doses of 131I. In order to further assess the significance of this finding, retrospective analysis of patients with persistent thyroglobulinemia and negative WBS was performed for evidence of surgically amenable disease. Seven out of seventeen patients had neck ultrasound and/or computerized tomography (neck +/- chest) showing the presence of pathologically confirmed malignant masses ranging from 1 to 4 cm in size. Their serum Tg while on L-thyroxine ranged between 2.4 and 1173 pmol/l. Removal of the identified masses resulted in a greater than 75% reduction in serum Tg in four out of five patients in the group. One patient achieved a serum Tg of < 1.5 pmol/l while hypothyroid. Empiric 131I treatment of eleven patients with persistent thyroglobulinemia resulted in demonstrated uptake on post-therapy scan in seven. Further study is needed to compare the efficacy, safety and cost of a diagnostic approach to radiologically identify and surgically resect identified disease versus empiric therapeutic 131I treatment and high-dose WBS in this group of patients. Patients with negative WBS and persistent thyroglobulinemia, even to levels < 4.5 pmol/l, may have significant foci of thyroid cancer in surgically accessible areas. This suggests the need for a redefinition or clarification of the term 'recurrence' in thyroid cancer.

scholarly journals [18F]-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin Levels

1999 ◽  
Vol 84 (7) ◽  
pp. 2291-2302 ◽  
Author(s):  
Weiping Wang ◽  
Homer Macapinlac ◽  
Steven M. Larson ◽  
Samuel D. J. Yeh ◽  
Timothy Akhurst ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Thyroid Cancer ◽  
Predictive Value ◽  
Fdg Pet ◽  
Residual Disease ◽  
False Negative ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission ◽  
Metastatic Thyroid Cancer

Progressive dedifferentiation of thyroid cancer cells leads to a loss of iodine-concentrating ability, with resultant false negative, whole body radioactive iodine scans in approximately 20% of all differentiated metastatic thyroid cancer lesions. We tested the hypothesis that all metastatic thyroid cancer lesions that did not concentrate iodine, but did produce thyroglobulin (Tg), could be localized by [18F]2-fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET). We performed FDG-PET on 37 patients with differentiated thyroid cancer after surgery and radioiodine ablation who had negative diagnostic 131I whole body scans during routine follow-up. Serum Tg, Tg autoantibodies, neck ultrasounds, and other clinically indicated imaging procedures were performed to detect residual disease. In those with elevated Tg levels, FDG-PET localized occult disease in 71%, was false positive in one, and was false negative in five patients. The majority of false negative FDG-PET occurred in patients with minimal cervical adenopathy. Surgical resections, biopsies, 131I therapy, and differentiation therapy were performed based on the PET results. The FDG-PET result changed the clinical management in 19 of the 37 patients. In patients with elevated Tg levels, FDG-PET had a positive predictive value of 92%. In patients with low Tg levels, FDG-PET had a negative predictive value of 93%. No FDG-PET scans were positive in stage I patients; however, they were always positive in stage IV patients with elevated Tg levels. An elevated TSH level (i.e. hypothyroidism) did not increase the ability to detect lesions. FDG-PET is able to localize residual thyroid cancer lesions in patients who have negative diagnostic 131I whole body scans and elevated Tg levels, although it was not sensitive enough to detect minimal residual disease in cervical nodes.

Validation of a Simple Thyroid Cancer Dosimetry Model Based on the Fractional Whole-Body Retention at 48 Hours Post-Administration of 131I

Thyroid ◽  
2015 ◽  
Vol 25 (12) ◽  
pp. 1347-1350 ◽  
Author(s):  
Frank Atkins ◽  
Douglas Van Nostrand ◽  
Shari Moreau ◽  
Kenneth Burman ◽  
Leonard Wartofsky
Keyword(s):  
Thyroid Cancer ◽  
Whole Body ◽  
Model Based ◽  
Body Retention

Comparison of 131I whole-body imaging, 131I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer

2011 ◽  
Vol 38 (8) ◽  
pp. 1459-1468 ◽  
Author(s):  
Jong-Ryool Oh ◽  
Byung-Hyun Byun ◽  
Sun-Pyo Hong ◽  
Ari Chong ◽  
Jahae Kim ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Fdg Pet ◽  
Whole Body ◽  
Whole Body Imaging ◽  
Body Imaging ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Metastatic Thyroid Cancer

Comparison of whole-body 18 F-FDG PET, 99m Tc-MIBI SPET, and post-therapeutic 131 I-Na scintigraphy in the detection of metastatic thyroid cancer

2004 ◽  
Vol 31 (4) ◽  
pp. 491-498 ◽  
Author(s):  
Masahiro Iwata ◽  
Kanji Kasagi ◽  
Takashi Misaki ◽  
Keiichi Matsumoto ◽  
Yasuhiro Iida ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Fdg Pet ◽  
Whole Body ◽  
Metastatic Thyroid Cancer

scholarly journals Head-to-Head Comparison of 68Ga-PSMA-11 and 131I in the Follow-Up of Well-Differentiated Metastatic Thyroid Cancer: A New Potential Theragnostic Agent

2021 ◽  
Vol 12 ◽  
Author(s):  
Quetzali Pitalua-Cortes ◽  
Francisco Osvaldo García-Perez ◽  
Joel Vargas-Ahumada ◽  
Sofia Gonzalez-Rueda ◽  
Edgar Gomez-Argumosa ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Lymph Nodes ◽  
Lesion Detection ◽  
Whole Body ◽  
Image Method ◽  
Psma Pet ◽  
Pet Ct ◽  
Well Differentiated ◽  
Metastatic Thyroid Cancer

IntroductionThyroid cancer is the main endocrine neoplasia worldwide, for which 131I therapy is the cornerstone treatment. One of the main problems of follow up in patients with this type of cancer, is the need for thyroglobulin stimulation, not to mention the poor availability of 123I or 124I, to perform studies with a higher degree of sensitivity. Prostatic Specific Membrane Antigen (PSMA) PET/CT has demonstrated to be quite useful in a diversified number of neoplasms, on behalf of its capacity of evaluating the extent of type II carboxypeptidase expression in vascular endothelium. The end point of this article is to assess whether this novel image method possesses applicability in thyroid neoplasms follow up, for diagnostic and potentially therapeutic purposes.MethodsWe retrospectively evaluated well differentiated metastatic thyroid cancer patients, who underwent a post therapeutic 131I dose whole body scan (WBS) and complementary SPECT/CT, as well as 68Ga-PSMA–11 PET/CT.ResultsTen patients with differentiated thyroid cancer were included, of whom 80% were women and 20% men, mean age was 58 years old (± 11.6). Sixty-four metastatic lesions were analyzed, 67.19% had papillary histology and 32.81% were follicular type, the most affected site of metastases was bone in 57.81%, followed by lung 17.19%, lymph nodes 7.81%, postoperative thyroid bed 4.69%, brain 4.69% and others 7.81%. 68Ga PSMA-11 PET/CT detected 64/64 lesions, all of them also identified by computed tomography (CT), whereas 131I SPECT/CT detected 55/64 lesions. Discrepant lesions were localized in lung 44.4%, brain 22.2%, postoperative thyroid bed 11.1%, lymph nodes 11.1% and bone 11.1%. The degree of correspondence among observers was outstanding for both radiotracers, but close upon perfect for PSMA-11 (κ = 0.98; 95% CI, 0.80 – 0.91), as opposed to 131 I (κ = 0.86; 95% CI, 0.71 – 0.76).Conclusions68Ga-PSMA PET/CT showed an utterly superior capability for metastatic lesion detection when compared to 131I SPECT/CT. These findings suggest that PSMA PET/CT could possibly and precociously identify radioiodine refractoriness. PSMA uptake values not only expedite diagnosis, but also award it the ability to be used for therapeutic intents.

Sign in / Sign up

Export Citation Format

Share Document